Philip D. Greenberg, M.D.

Professor of Oncology and Immunology, University of Washington; Investigator, Parker Institute for Cancer Immunotherapy, Fred Hutchinson Cancer Research Center

Immunology, Immuno-oncology, Cancer Biology, Genetic Engineering, Cell Therapy


BA - Washington University, St. Louis

MD - State University of New York

Residency - University of California, San Diego

Postdoctoral Fellow - University of California, San Diego  


American Society of Clinical Investigation Fellow

Association of American Physicians Fellow, 1998

American Association for the Advancement of Science Fellow, 2007

Cancer Research Institute’s William B. Coley Award for Distinguished Research in Tumor Immunology, 2011

Society for Immunotherapy of Cancer Richard Smalley Memorial Award, 2018

Fellow of the American Association for Cancer Research Academy, 2019

Distinguished Fellow of the American Association of Immunologists, 2019

American Society of Hematology E. Donnall Thomas Prize for Pioneering Research Achievements in Hematology, 2019

Precision Medicine World Conference (PMWC) Luminary Award, 2020


Co-Founder: Targeted Genetics (NASDAQ: TGEN), Juno Therapeutics (acquired by Celgene), Affini-T Therapeutics

Board of Directors: Nestle SA, Vilcek Foundation

Scientific Advisory Board: Celsius Therapeutics, Earli, Immunoscpate, Metagenomi, Elpiscience Biopharma

MEMBER OF Investment Committee

Associated Portfolio Companies

No items found.